Please login to the form below

Not currently logged in
Email:
Password:

Stephen MacMillan resigns as Stryker’s chair, president and CEO

Curt Hartman takes over as interim CEO and William Parfet steps in as non-executive chairman at the US medical technology firm

Stephen MacMillan has resigned from his roles as chair, president and CEO of Stryker Corporation.

The US-based medical technology firm cited family reasons as the motivation for the departure of MacMillan, who had been chair for two years, CEO for seven years and president for nine years.

MacMillan said: "It has been an enormous privilege to have led Stryker during this period of important change and growth.

“As I look ahead to the next chapter in my life, I remain confident that the team will continue to execute Stryker's strategy with distinction and that the company will enjoy continued success in the future."

Replacing MacMillan as interim CEO is Stryker's current chief financial officer, Curt Hartman, while lead independent director William Parfet will take over as non-executive chairman.

Hartman, who has been with the company since 1990, has served as chief financial officer and vice president since 2009 and his previous roles include holding the post of global president of Stryker Instruments.

Parfet has been a director at Stryker for almost 20 years alongside his role as chair and CEO of drug safety and pharmaceutical development company MPI Research.

15th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics